KBI Biopharma vs Rentschler Biopharma: CDMO Comparison
Side-by-side comparison of KBI Biopharma and Rentschler Biopharma on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Rentschler Biopharma holds 2 active EMA GMP certificates; KBI Biopharma does not appear in EudraGMDP.
- KBI Biopharma maintains 1 MHRA / UK GMP certificate; Rentschler Biopharma does not.
On a 13-modality CDMO landscape, both KBI Biopharma and Rentschler Biopharma qualify as Recombinant Proteins manufacturers; KBI Biopharma carries the higher composite Signal Score for Recombinant Proteins programs in this comparison.
What to evaluate for Recombinant Proteins programs
Both KBI Biopharma and Rentschler Biopharma qualify as Recombinant Proteins CDMOs. When choosing between them for Recombinant Proteins programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Expression host & scale
Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target.
Purification & analytics
Downstream complexity (multiple chromatography steps, refolding for E. coli) drives cost and timeline. Ask about the orthogonal analytics package — purity, identity, potency.
Regulatory readiness
Clean FDA 483 history and EMA/MHRA GMP coverage matter — both are shown above and on each profile.
Capacity & commercial readiness
For programs heading to BLA, evaluate validated commercial scale and any approved-product track record.
Frequently asked: KBI Biopharma vs Rentschler Biopharma
Which has the stronger FDA inspection record, KBI Biopharma or Rentschler Biopharma?
Both KBI Biopharma and Rentschler Biopharma maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. KBI Biopharma has 1 FDA inspection on record; Rentschler Biopharma has 1.
How do KBI Biopharma and Rentschler Biopharma compare on European GMP coverage?
KBI Biopharma holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Rentschler Biopharma holds 2 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for Recombinant Proteins manufacturing — KBI Biopharma or Rentschler Biopharma?
Both KBI Biopharma and Rentschler Biopharma are tagged as Recombinant Proteins CDMOs in our directory, so both are credible options for Recombinant Proteins programs. The most important differentiator for Recombinant Proteins selection is typically expression host & scale: Microbial hosts (E. coli, P. pastoris) suit non-glycosylated proteins; mammalian (CHO) is the workhorse for glycoproteins. Confirm validated bioreactor scale and the CDMO's experience with your target. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
KBI Biopharma carries a Signal Score of 84/100 and Rentschler Biopharma carries 80/100 — essentially tied for KBI Biopharma. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →